The Foundation for Tomorrow's Medicines: Complete Accessible Sequencing Solutions

Q4 Biochemistry, Genetics and Molecular Biology

Genetic Engineering & Biotechnology News Pub Date : 2023-10-01 DOI:10.1089/gen.43.10.17

引用次数: 0

Abstract

Genetic Engineering & Biotechnology NewsVol. 43, No. 10 Sponsored ContentThe Foundation for Tomorrow's Medicines: Complete Accessible Sequencing SolutionsComplete Genomics says it is driving the field forward with efficient, accurate, and accessible complete whole genome sequencing solutionsPublished Online:13 Oct 2023https://doi.org/10.1089/gen.43.10.17AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 43Issue 10Oct 2023 Information© 2023 by GEN PublishingTo cite this article:The Foundation for Tomorrow's Medicines: Complete Accessible Sequencing Solutions.Genetic Engineering & Biotechnology News.Oct 2023.43-43.http://doi.org/10.1089/gen.43.10.17Published in Volume: 43 Issue 10: October 13, 2023PDF download

查看原文本刊更多论文

未来药物基金会:完全可获得的测序解决方案

基因工程与生物技术新闻卷。43、第10号赞助内容明天的药物基金会:完整基因组公司表示，该公司正以高效、准确、和可访问的完整全基因组测序解决方案发表在线:13 Oct 2023https://doi.org/10.1089/gen.43.10.17AboutSectionsView文章查看全文pdf /EPUB权限和citationspermissions下载CitationsTrack citations添加到收藏回到出版物共享分享在facebook上推特链接在redditemail查看文章figuresreferencesrelateddetails卷43期10Oct 2023信息©2023 by GEN publishing引用这篇文章:明天的药物的基础:完整的可访问测序解决方案。基因工程与生物技术新闻。Oct 2023.43-43.http://doi.org/10.1089/gen.43.10.17Published in Volume: 43 Issue 10: October 13, 2023PDF下载

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Genetic Engineering & Biotechnology News 工程技术-生物工程与应用微生物

CiteScore

0.20

自引率

0.00%

发文量

210

审稿时长

3-6 weeks

期刊介绍： Genetic Engineering & Biotechnology News (GEN) is the flagship publication of Mary Ann Liebert, Inc. Launched in 1980, GEN was the first publication in this field and remains the key driver in the explosion of the industry, paving the way for the development of new technologies and applications, investment growth, and career opportunities. With nearly 40 years of publishing experience, GEN maintains unrivaled integrity, influence, and expertise that plays a pivotal role in driving the productivity and growth of the industry. Through its cornerstone Magazine, high-frequency newsletters, and dynamic suite of multimedia resources, GEN is the 360-degree resource that researchers and executives depend on for information that is pivotal for their organization’s success. GEN’s breadth of editorial coverage is unrivaled in the industry, providing exclusive coverage of the entire bioproduct lifecycle across five key pillars: Drug Discovery, Bioprocessing, OMICS, Translational Medicine, and Gene Editing.